Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - paracetamol, quantity: 500 mg; codeine phosphate hemihydrate, quantity: 30 mg - tablet, uncoated - excipient ingredients: potassium sorbate; maize starch; povidone; purified talc; stearic acid; magnesium stearate; microcrystalline cellulose; croscarmellose sodium; pregelatinised maize starch - paracetamol/codeine gh 500/30 is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - amoxicillin trihydrate 575mg equivalent to amoxycillin 500 mg;   - capsule - 500 mg - active: amoxicillin trihydrate 575mg equivalent to amoxycillin 500 mg   excipient: gelatin colloidal anydrous silica magnesium stearate purified talc sodium starch glycolate - amoxicillin should be used in accordance with local antibiotic-prescribing information guidelines and local susceptibility data. amoxicillin may be useful in instituting therapy prior to bacteriology; however bacteriological studies to determine the causative organisms and their sensitivity to amoxicillin should be performed. susceptibility to amoxicillin will vary with geography and time and local susceptibility data should be consulted where available and microbiological sampling and susceptibility testing performed where necessary. treatment of infection: amoxicillin is indicated in the treatment of infections due to susceptible organisms. skin and skin structure: staphylococcus, non-penicillinase producing; streptococcus; e. coli. respiratory (acute and chronic): h. influenzae; streptococcus; s. pneumoniae; staphylococcus, non-penicillinase-producing; e.coli. genitourinary tract (complicated and uncomplicated, acute and chronic): e.coli, p. mirabilis and s. faecalis. gonorrhoea: n. gonorrhoeae (non-penicillinase producing). prophylaxis for endocarditis: amoxicillin may be used for the prevention of bacteraemia, associated with procedures such as dental extraction, in patients at risk of developing bacterial endocarditis, such as those with a prosthetic heart valve or those who have previously had endocarditis.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - lamotrigine, quantity: 200 mg - tablet, uncoated - excipient ingredients: magnesium stearate; microcrystalline cellulose; sodium starch glycollate; maize starch; lactose monohydrate - lamotrigine gh (lamotrigine) is an anti-epileptic drug for the treatment of partial and generalised seizures in adults and children over 12 years of age.,there is extensive experience with lamotrigine used initially as ?add-on therapy?. the use of lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant anti-epileptic drugs (aeds).,initial monotherapy treatment in newly diagnosed paediatric patients is not recommended (see section 5.1 pharmacodynamic properties - clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - lamotrigine, quantity: 100 mg - tablet, uncoated - excipient ingredients: magnesium stearate; sodium starch glycollate; maize starch; lactose monohydrate; microcrystalline cellulose - lamotrigine gh (lamotrigine) is an anti-epileptic drug for the treatment of partial and generalised seizures in adults and children over 12 years of age.,there is extensive experience with lamotrigine used initially as ?add-on therapy?. the use of lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant anti-epileptic drugs (aeds).,initial monotherapy treatment in newly diagnosed paediatric patients is not recommended (see section 5.1 pharmacodynamic properties - clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - lamotrigine, quantity: 50 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate; microcrystalline cellulose; lactose monohydrate; maize starch; magnesium stearate - lamotrigine gh (lamotrigine) is an anti-epileptic drug for the treatment of partial and generalised seizures in adults and children over 12 years of age.,there is extensive experience with lamotrigine used initially as ?add-on therapy?. the use of lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant anti-epileptic drugs (aeds).,initial monotherapy treatment in newly diagnosed paediatric patients is not recommended (see section 5.1 pharmacodynamic properties - clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - lamotrigine, quantity: 25 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate; lactose monohydrate; magnesium stearate; microcrystalline cellulose; maize starch - lamotrigine gh (lamotrigine) is an anti-epileptic drug for the treatment of partial and generalised seizures in adults and children over 12 years of age.,there is extensive experience with lamotrigine used initially as ?add-on therapy?. the use of lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant anti-epileptic drugs (aeds).,initial monotherapy treatment in newly diagnosed paediatric patients is not recommended (see section 5.1 pharmacodynamic properties - clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - paracetamol, quantity: 10 mg/ml - injection, solution - excipient ingredients: cysteine hydrochloride monohydrate; mannitol; water for injections; nitrogen - paracetamol 10 mg/ml, solution for infusion is indicated for the relief of mild to moderate pain and the reduction of fever where an intravenous route of administration is considered clinically necessary.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - paracetamol, quantity: 10 mg/ml - injection, solution - excipient ingredients: cysteine hydrochloride monohydrate; nitrogen; mannitol; water for injections - paracetamol 10 mg/ml, solution for infusion is indicated for the relief of mild to moderate pain and the reduction of fever where an intravenous route of administration is considered clinically necessary.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - paracetamol, quantity: 10 mg/ml - injection, solution - excipient ingredients: cysteine hydrochloride monohydrate; mannitol; water for injections; nitrogen - paracetamol 10 mg/ml, solution for infusion is indicated for the relief of mild to moderate pain and the reduction of fever where an intravenous route of administration is considered clinically necessary.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - paracetamol, quantity: 10 mg/ml - injection, solution - excipient ingredients: cysteine hydrochloride monohydrate; nitrogen; mannitol; water for injections - paracetamol 10 mg/ml, solution for infusion is indicated for the relief of mild to moderate pain and the reduction of fever where an intravenous route of administration is considered clinically necessary.